Corn BW, Marcus SM, Topham A et al (1997) Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer 79:2409–2413

CAS  PubMed  Google Scholar 

Daras M, DeAngelis LM (2013) Management of elderly patients with primary central nervous system lymphoma. Curr Neurol Neurosci Rep 13:344

PubMed  Google Scholar 

Ferreri AJ, Blay JY, Reni M et al (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266–272

PubMed  Google Scholar 

Abrey LE, Ben-Porat L, Panageas KS et al (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24:5711–5715

PubMed  Google Scholar 

Tateishi K, Miyake Y, Nakamura T et al (2021) Primary central nervous system lymphoma: clinicopathological and genomic insights for therapeutic development. Brain Tumor Pathol 38:173–182

PubMed  Google Scholar 

Camilleri-Broet S, Criniere E, Broet P et al (2006) A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 107:190–196

CAS  PubMed  Google Scholar 

Niparuck P, Boonsakan P, Sutthippingkiat T et al (2019) Treatment outcome and prognostic factors in PCNSL. Diagn Pathol 14:56

PubMed  PubMed Central  Google Scholar 

Marcus C, Maragkos GA, Alterman RL et al (2021) GCB-type is a favorable prognostic factor in primary CNS diffuse large B-cell lymphomas. J Clin Neurosci 83:49–55

PubMed  Google Scholar 

Hatzl S, Posch F, Deutsch A et al (2020) Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma. Hematol Oncol 38:277–283

CAS  PubMed  PubMed Central  Google Scholar 

Furuse M, Kuwabara H, Ikeda N et al (2020) PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma. BMC Cancer 20:277

CAS  PubMed  PubMed Central  Google Scholar 

Cho H, Kim SH, Kim SJ et al (2017) Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma. Oncotarget 8:87317–87328

PubMed  PubMed Central  Google Scholar 

Hayano A, Komohara Y, Takashima Y et al (2017) Programmed cell death ligand 1 expression in primary central nervous system lymphomas: a clinicopathological study. Anticancer Res 37:5655–5666

CAS  PubMed  Google Scholar 

Cho I, Lee H, Yoon SE et al (2020) Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. BMC Cancer 20:120

CAS  PubMed  PubMed Central  Google Scholar 

Takashima Y, Kawaguchi A, Sato R et al (2019) Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL. Sci Rep 9:10004

PubMed  PubMed Central  Google Scholar 

Berghoff AS, Ricken G, Widhalm G et al (2014) PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). Clin Neuropathol 33:42–49

PubMed  Google Scholar 

Sasayama T, Tanaka K, Mizowaki T et al (2016) Tumor-associated macrophages associate with cerebrospinal fluid interleukin-10 and survival in primary central nervous system lymphoma (PCNSL). Brain Pathol 26:479–487

CAS  PubMed  Google Scholar 

Komohara Y, Horlad H, Ohnishi K et al (2011) M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma. J Clin Exp Hematop 51:93–99

PubMed  Google Scholar 

Marcelis L, Antoranz A, Delsupehe AM et al (2020) In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy. Cancer Immunol Immunother 69:1751–1766

CAS  PubMed  Google Scholar 

Jamal SE, Li S, Bajaj R et al (2014) Primary central nervous system Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly: a clinicopathologic study of five cases. Brain Tumor Pathol 31:265–273

CAS  PubMed  Google Scholar 

Sugita Y, Terasaki M, Niino D et al (2010) Epstein–Barr virus-associated primary central nervous system lymphomas in immunocompetent elderly patients: analysis for latent membrane protein-1 oncogene deletion and EBNA-2 strain typing. J Neurooncol 100:271–279

CAS  PubMed  Google Scholar 

Kitai R, Matsuda K, Adachi E et al (2010) Epstein–Barr virus-associated primary central nervous system lymphoma in the Japanese population. Neurol Med Chir (Tokyo) 50:114–118

Google Scholar 

Asano K, Yamashita Y, Ono T et al (2021) The real-world status and risk factors for a poor prognosis in elderly patients with primary central nervous system malignant lymphomas: a multicenter, retrospective cohort study of the Tohoku Brain Tumor Study Group. Int J Clin Oncol 27:77–94

PubMed  Google Scholar 

Topalian SL, Taube JM, Anders RA et al (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275–287

CAS  PubMed  PubMed Central  Google Scholar 

Chow LQM, Haddad R, Gupta S et al (2016) Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 34:3838–3845

CAS  PubMed  PubMed Central  Google Scholar 

Green MR, Monti S, Rodig SJ et al (2010) Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116:3268–3277

CAS  PubMed  PubMed Central  Google Scholar 

Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282

CAS  PubMed  Google Scholar 

Green TM, Young KH, Visco C et al (2012) Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3460–3467

CAS  PubMed  Google Scholar 

Matsubara T, Takada K, Azuma K et al (2019) A Clinicopathological and prognostic analysis of PD-L2 expression in surgically resected primary lung squamous cell carcinoma. Ann Surg Oncol 26:1925–1933

PubMed  Google Scholar 

Tomita S, Kikuti YY, Carreras J et al (2015) Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan. Mod Pathol 28:1286–1296

CAS  PubMed  Google Scholar 

Hu S, Xu-Monette ZY, Tzankov A et al (2013) MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121:4021–4031 (quiz 4250)

CAS  PubMed  PubMed Central  Google Scholar 

Abrey LE, Batchelor TT, Ferreri AJ et al (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034–5043

PubMed  Google Scholar 

Wang CC, Carnevale J, Rubenstein JL (2014) Progress in central nervous system lymphomas. Br J Haematol 166:311–325

CAS  PubMed  PubMed Central  Google Scholar 

Kluin PMDM, Ferry JA (2008) Primary diffuse large B-cell lymphoma of the CNS. IARC Press, Lyon

Google Scholar 

Shiozawa E, Yamochi-Onizuka T, Takimoto M et al (2007) The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leuk Res 31:1579–1583

CAS  PubMed  Google Scholar 

Phang KC, Hussin NH, Abdul RF et al (2019) Characterisation of immunogenotypes of diffuse large B-cell lymphoma. Malays J Pathol 41:101–124

CAS  PubMed  Google Scholar 

Umemura H, Homma M, Shiozwa E et al (2012) Immunohistochemical analysis of the cell cycle-associated proteins in diffuse large B-cell lymphoma. Showa IKaishi 72:108–117

Google Scholar 

Seki R, Ohshima K, Fujisaki T et al (2009) Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 100:1842–1847

CAS  PubMed  Google Scholar 

Radotra BD, Parkhi M, Chatterjee D et al (2020) Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: experience from a Tertiary Center in North India. Surg Neurol Int 11:424

PubMed  PubMed Central  Google Scholar 

Aukema SM, Siebert R, Schuuring E et al (2011) Double-hit B-cell lymphomas. Blood 117:2319–2331

CAS  PubMed  Google Scholar 

Riedell PA, Smith SM (2018) Double hit and double expressors in lymphoma: definition and treatment. Cancer 124:4622–4632

PubMed  Google Scholar 

Ma Z, Niu J, Cao Y et al (2020) Clinical significance of “double-hit” and “double-expression” lymphomas. J Clin Pathol 73:126–138

CAS  PubMed  Google Scholar 

Xu-Monette ZY, Xiao M, Au Q et al (2019) Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL. Cancer Immunol Res 7:644–657

CAS  PubMed  Google Scholar 

Godfrey J, Tumuluru S, Bao R et al (2019) PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype. Blood 133:2279–2290

CAS  PubMed  PubMed Central  Google Scholar 

Wu P, Wu D, Li L et al (2015) PD-L1 and survival in solid tumors: a meta-analysis. PLoS ONE 10:e0131403

PubMed  PubMed Central  Google Scholar 

Zhao T, Li C, Wu Y et al (2017) Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: a meta-analysis. PLoS ONE 12:e0176822

PubMed  PubMed Central  Google Scholar 

Marchesi F, Cirillo M, Bianchi A et al (2015) High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma. Hematol Oncol 33:110–112

CAS  PubMed  Google Scholar